Homocysteine Levels in Patients Undergoing Open-Heart Surgery
DOI:
https://doi.org/10.1532/HSF98.20041147Abstract
Background: The aim of this prospective study was to determine the levels of plasma homocysteine (HCY) in patients who have undergone open-heart surgery for ischemic heart disease (IHD) or nonischemic heart disease (NIHD) and to evaluate whether an association is present between hyperhomocysteinemia and coronary artery disease.
Material and Methods: We investigated prospectively 30 patients who underwent open-heart surgery. Of these patients, 15 had IHD, and 15 had NIHD such as mitral and/or aortic valve disease. The 2 groups were well matched for age, sex, body mass index, and blood pressure. In all patients HCY was assayed by high performance liquid chromatography preoperatively and on the first, second, and third day postoperatively.
Results: The mean age of the patients was 57.2 years in group IHD and 52.6 years in group NIHD. The male:female ratio was 8:7 in group IHD and 7:8 in group NIHD. Of 15 patients in group IHD, 13 had hyperhomocysteinemia and 2 had normal plasma HCY levels. Of 15 patients in NIHD group, 1 had hyperhomocysteinemia and the others had normal plasma HCY levels. Preoperative plasma HCY levels of all patients in the IHD group were significantly lower during all subsequent time periods, whereas preoperative plasma HCY levels in the NIHD group were lower only on the first day post-surgery (P < .05).
Conclusions: Our data suggest that plasma HCY levels in patients with IHD are associated with the development of atherogenesis and coronary artery disease. For this reason, HCY levels should be measured routinely and treated appropriately in patients with risk factors for atherosclerosis.
References
Boushey CJ, Beresford SA, Omenn GS, et al. 1995. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274:1049-57.nBozkurt A, Toyaksi H, Acarturk E, et al. 2003. The effects of hyperhomocysteinemia on the presence, extent, and severity of coronary artery disease. Jpn Heart J 44:357-68.nChao CL, Tsai HH, Lee CM, et al. 1999. The graded effect of hyperhomocysteinemia on the severity and extent of coronary atherosclerosis. Atherosclerosis 147:379-86.nEikelboom JW, Lonn E, Genest J Jr, et al. 1999. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 131:363-75.nHackam DG, Peterson JC, Spence JD. 2000. What level of plasma homocyst(e)ine should be treated? Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocyst(e)ine levels above and below 14 $mUmol/L. Am J Hypertens 13:105-10.nHughes S. 2003. Novel cardiovascular risk factors. J Cardiovasc Nurs 18:131-8.nLi J, Zhang Y, Yao X, et al. 2002. Effect of homocysteine on the L-arginine/nitric oxide synthase/nitric oxide pathway in human platelets. Heart Vessels 16:46-50.nMalinow MR, Bostom AG, Krauss RM. 1999. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 99:178-82.nMayer EL, Jacobsen DW, Robinson K. 1996. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 27:517-27.nMilosevic-Tosic M, Borota J. 2002. Hyperhomocysteinemia: a risk factor for development of occlusive vascular diseases. Med Pregl 55:385-91.nPrasad K. 1999. Homocysteine, a risk factor for cardiovascular disease. Int J Angiol 8:76-86.nSmith SC, Greenland P, Grundy SM. 2000. AHA Conference Proceedings. Prevention conference V: Beyond secondary prevention: Identifying the high-risk patient for primary prevention: executive summary. American Heart Association. Circulation 101:111-6.nWilcken DE, Wilcken B. 1997. The natural history of vascular disease in homocystinuria and the effects of treatment. J Inherit Metab Dis 20:295-300.nWoo KS, Chook P, Lolin YI, et al. 1997. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 96:2542-4.n
Published
How to Cite
Issue
Section
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).